Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 2 of 4 for:    bnc210

A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder (PREVAIL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05193409
Recruitment Status : Recruiting
First Posted : January 14, 2022
Last Update Posted : January 14, 2022
Information provided by (Responsible Party):
Bionomics Limited

Brief Summary:
The purpose of this study is to assess the effects of an acute dose of BNC210 compared to placebo on reducing anxiety provoked by a speaking challenge and measured using the Subjective Units of Distress Scale (SUDS) in patients with Social Anxiety Disorder (SAD).

Condition or disease Intervention/treatment Phase
Social Anxiety Disorder Drug: 225 mg BNC210 Drug: 675 mg BNC210 Drug: Placebo Phase 2

Detailed Description:
This is a randomized, double-blind, placebo-controlled, 3-arm, parallel-group, multi-center study. Participants will attend a Screening Visit to confirm eligibility and then return to the clinic within 14 days to be randomized into the study. Randomized participants will receive a single dose of their allocated study intervention (225 mg BNC210, 675 mg BNC210 or placebo) and approximately 1 hour later participate in a speaking challenge. After 1 week, a safety follow-up assessment will be conducted by phone/video conference.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of BNC210 Compared to Placebo for the Acute Treatment of Social Anxiety Disorder
Estimated Study Start Date : January 2022
Estimated Primary Completion Date : October 2022
Estimated Study Completion Date : November 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anxiety

Arm Intervention/treatment
Experimental: 225 mg BNC210 Drug: 225 mg BNC210
225 mg BNC210

Experimental: 675 mg BNC210 Drug: 675 mg BNC210
675 mg BNC210

Placebo Comparator: Placebo Drug: Placebo

Primary Outcome Measures :
  1. Subjective Units of Distress Scale (SUDS) - speaking challenge performance phase [ Time Frame: 1 Day ]

Secondary Outcome Measures :
  1. Subjective Units of Distress Scale (SUDS) - speaking challenge anticipation phase [ Time Frame: 1 Day ]
  2. State-Trait Anxiety Inventory (State component; STAI-State) [ Time Frame: 1 Day ]
  3. Self-Statements During Public Speaking Scale (Negative Self-Statements subscale; SSPS-N) [ Time Frame: 1 Day ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Participant has a current diagnosis of Social Anxiety Disorder (SAD) as defined in DSM-5 and confirmed by Structured Clinical Interview for DSM-5 Disorders - Clinical Trials version (SCID-5-CT).
  • Liebowitz Social Anxiety Scale (LSAS) total score of ≥70
  • Suitable contraception use in line with protocol requirements
  • Ability to swallow tablets

Exclusion Criteria:

  • History of schizophrenia, bipolar disorder, or psychotic disorders, or has a current clinically predominant diagnosis of any other Axis I disorder, other than SAD
  • Hamilton Rating Scale for Depression (HAM-D) score of ≥18
  • Moderate or severe alcohol-use disorder, or any other substance-use disorder (any severity) in the past 12 months
  • Use of psychotropic medications within 30 days of screening. Daily use of benzodiazepines within 90 days of screening.
  • Previous participation in a study that involved a speaking challenge.
  • Any clinically significant medical history or findings as determined by the Investigator that could interfere with the objectives of the study or put the participant at risk

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT05193409

Layout table for location contacts
Contact: BNC210 Clinical Studies Bionomics Limited +61 8 8150 7400

Layout table for location information
United States, Florida
PREVAIL Study Clinical Trial Site Recruiting
Lauderhill, Florida, United States, 33319
Sponsors and Collaborators
Bionomics Limited
Layout table for additonal information
Responsible Party: Bionomics Limited Identifier: NCT05193409    
Other Study ID Numbers: BNC210.013
First Posted: January 14, 2022    Key Record Dates
Last Update Posted: January 14, 2022
Last Verified: January 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Anxiety Disorders
Phobia, Social
Mental Disorders
Phobic Disorders